Compare DexCom, Inc. (DXCM) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Meta Platforms Inc — how do they compare? DexCom, Inc. trades at $78.55 (market cap $28.06B), while Meta Platforms Inc trades at $680.43 (market cap $1.73T). The key difference: Meta Platforms Inc is far larger — about 61.7× DexCom, Inc.'s market cap, and Meta Platforms Inc pays a 0.31% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | META | |
|---|---|---|
Market Cap | $28.06B | $1.73T |
Sector | Health | Media |
52-Week High | $89.53 | $790.00 |
52-Week Low | $54.84 | $525.72 |
Enterprise Value | $27.03B | $1.74T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
META stock trades at $661.04, up 0.66% today, with a bullish technical signal driven by moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $10.44 versus $6.70 expected, and maintains robust profitability with a 32.84% net income margin. Recent news highlights the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, though it faces a youth addiction lawsuit in Massachusetts.
The outlook remains positive with a consensus price target of $815.44, implying 23% upside, supported by 79% analyst buy ratings. Key risks include regulatory lawsuits and high capital expenditure for AI investments. Revenue growth is projected to reach $215.0 billion in 2026, with net income rising to $70.6 billion, reinforcing its strong fundamental position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
